Loading...
•
Sep 30, 2023
Lexicon Pharmaceuticals Q3 2023 Earnings Report
Reported financial results for Q3 2023 and provided a business update, highlighting the commercial launch of INPEFA and the advancement of LX9211 into late-stage development.
Key Takeaways
Lexicon Pharmaceuticals reported Q3 2023 financial results, featuring the commercial launch of INPEFA, which saw increasing prescription demand, and the progression of LX9211 into late-stage development for diabetic peripheral neuropathic pain. The company is seeing important formulary wins, with some of the more notable becoming effective on November 1st. Revenue for the quarter was $0.2 million, and the net loss was $50.5 million, or $0.21 per share.
Commercial launch of INPEFA (sotagliflozin) shows meaningful progress in Q3 with increasing demand across the cardiology community.
Significant formulary inclusions effective in Q4 opening the opportunity for further commercial acceleration into 2024 and beyond.
LX9211 moving into late-stage development for the treatment of diabetic peripheral neuropathic pain.
First patient expected to be enrolled in early December 2023 for LX9211's Phase 2b dose optimization study.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Revenue by Segment
Revenue by Segment
Net Product Revenue
CapyFin.comRoyalties and Other Revenue
CapyFin.com Forward Guidance
Lexicon expects continued acceleration of INPEFA momentum into 2024, driven by formulary wins and increasing uptake from physicians. They also anticipate enrolling the first patient in early December 2023 for LX9211's Phase 2b dose optimization study.
Positive Outlook
- Momentum behind INPEFA will continue to accelerate as they enter 2024
- Additional formulary wins expected
- Increasing uptake from a broadening base of priority physicians
- Continued progress with the launch of INPEFA
- Advancement of LX9211 into late-stage development
Challenges Ahead
- Risk relating to Lexicon’s ability to meet its capital requirements
- Risk relating to successfully commercialize its approved products
- Risk relating to successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines
- Risk relating to achieve its operational objectives
- Risk relating to obtain patent protection for its discoveries and establish strategic alliances
Revenue & Expenses
Visualization of income flow from segment revenue to net income